Fusix Biotech products

As multi-mechanistic antitumor agents, oncolytic viruses are emerging to be potent immunotherapeutic treatment options in different tumor indications. Oncoytic viruses specifically replicate in tumor cells due to altered signalling pathways supporting the tumor’s immune esape, leaving open replication advantages for viruses susceptible to intact signaling pathways.

The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This results in an oncolytic virus platform with an excellent safety profile and effective replication kinetics. Tumor-selective replication leads to significant oncolytic activity, while fusion-based cell death adds to its potent immune-stimulatory properties. Together this results in tumor regression and systemic tumor-specific immunity.